Validation of the Korean Version of the Breakthrough Pain Assessment Tool in Cancer Patients

Shin, Jin Young; Cho, Sung Jung; Lee, Jungkwon; Choi, Youn Seon

doi:10.1016/j.jpainsymman.2017.07.011

Cited by 9 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 The Korean study did not report on the BPI total interference item. 14 In addition, the items about the worst and typical BTcP episode correlated well with all BPI pain intensity items in the present study, comparable to the Korean study. 14 However, in the U.K. study, these two items showed no correlation with BPI least pain intensity and current pain intensity.…”

Section: Discussionsupporting

confidence: 87%

“…14 In addition, the items about the worst and typical BTcP episode correlated well with all BPI pain intensity items in the present study, comparable to the Korean study. 14 However, in the U.K. study, these two items showed no correlation with BPI least pain intensity and current pain intensity. 10 Moreover, the BAT-DL items about distress and disruption of normal life correlated well to most BPI questions, comparable to the earlier studies.…”

Section: Discussionsupporting

confidence: 87%

“…The factor analysis showed that the BAT-DL loaded onto two factors, pain severity and impact factor and pain duration and medication efficacy factor, similar to the other validation studies in the U.K. and South Korea. 10,14 However, the last question, How much do the side effects from the breakthrough painkiller bother you?, loaded in the Korean version onto the second factor. Our present study confirmed the factors and factor loading of the original study.…”

Section: Discussionmentioning

confidence: 99%

“…10 The Korean study did not describe such an analysis. 14 Another comparison was based on the performance status. As expected, patients with a bad performance also scored worse at the BAT, especially on items about pain intensity, pain interference, and distress, as in the original study.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, an extra assessment took place, 24 hours after baseline, when patients were asked to complete the BAT-DL to assess the test-retest reliability of the questionnaire. 10,14 The BAT-DL contains 14 questions evaluating current pain management: nine questions related to pain and five questions related to the pain treatment. In six questions, 0e10 Numerical Rating Scales are used; in three questions, categorical scales are used; in four questions, free text; and in one question, a body shape outline to mark the site of the pain is used.…”

Section: Psychometric Propertiesmentioning

confidence: 99%

See 4 more Smart Citations

Validation of the Dutch Version of the Breakthrough Pain Assessment Tool in Patients With Cancer

Oldenmenger¹,

Lucas²,

Werff³

et al. 2020

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context. Essential for adequate management of breakthrough cancer pain is a combination of accurate (re-)assessment and a personalized treatment plan. The Breakthrough Pain Assessment Tool (BAT) has been proven to be a brief, multidimensional, reliable, and valid questionnaire for the assessment of breakthrough cancer pain.Objectives. The aim of this study was to examine the validity and reliability of the Dutch Language version of the BAT (BAT-DL) in patients with cancer.Methods. The BAT was forward-backward translated into the Dutch language. Thereafter, the psychometric properties of the BAT-DL were tested, that is factor structure, reliability (internal consistency and test-retest reliability), validity (content validity and construct validity), and the responsiveness to change.Results. The BAT-DL confirmed the two-factor structure in 170 patients with cancer: pain severity/impact factor and pain duration/medication efficacy factor. The Cronbach's alpha coefficient was 0.72, and the intraclass correlation for the testretest reliability was 0.81. The BAT-DL showed to be able to differentiate between different group of patients and correlated significantly with the Brief Pain Inventory. In addition, the BAT-DL was capable to detect clinically important changes over time.Conclusion. The BAT-DL is a valid and reliable questionnaire to assess breakthrough pain in Dutch patients with cancer and is a relevant questionnaire for daily practice.

show abstract

Section: Discussionsupporting

confidence: 87%